Search results

Filter (9 in use)

Type 2 selected

Status 2 selected

Last updated

Guidance programme 5 selected

1132 results

Relevance Date

  10. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)

    Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in

    Technology appraisal guidance
    Published
    View recommendations

  12. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

    Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction

    Technology appraisal guidance
    Published
    View recommendations

  13. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease

    Technology appraisal guidance
    Published
    View recommendations

  14. Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia

    Technology appraisal guidance
    Published
    View recommendations

  15. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for type 2 diabetes in adults

    Technology appraisal guidance
    Published
    View recommendations

  16. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

    Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults

    Technology appraisal guidance
    Published
    View recommendations

  17. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559)

    Evidence-based recommendations on axicabtagene ciloleucel therapy (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma

    Technology appraisal guidance
    Published
    View recommendations

  18. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

    Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up

    Technology appraisal guidance
    Published
    View recommendations

  21. Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)

    Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer in adults

    Technology appraisal guidance
    Published
    View recommendations

  23. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

    Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer

    Technology appraisal guidance
    Published
    View recommendations

  28. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

    Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C

    Technology appraisal guidance
    Last updated
    View recommendations

  29. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer

    Technology appraisal guidance
    Last updated
    View recommendations

  31. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

    Evidence-based recommendations on gefitinib (Iressa) for the first-line treatment of advanced or metastatic non-small-cell lung cancer (NSCLC)

    Technology appraisal guidance
    Published
    View recommendations

  32. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

    Evidence-based recommendations on rituximab (MabThera) for treating relapsed or refractory chronic lymphocytic leukaemia (CLL)

    Technology appraisal guidance
    Published
    View recommendations

  33. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab, etanercept, infliximab, rituximab and abatacept for treating rheumatoid arthritis after failure of a TNF inhibitor

    Technology appraisal guidance
    Published
    View recommendations

  34. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

    Technology appraisal guidance
    Published
    View recommendations

  35. Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

    Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

    Technology appraisal guidance
    Last updated
    View recommendations

  36. Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

    Evidence-based recommendations on bendamustine (Levact) for the first-line treatment of chronic lymphocytic leukaemia (CLL) of Binet stage B or C

    Technology appraisal guidance
    Published
    View recommendations

  37. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease

    Technology appraisal guidance
    Last updated
    View recommendations

  38. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

    Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

    Technology appraisal guidance
    Last updated
    View recommendations

  39. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol (Pletal), naftidrofuryl oxalate (Praxilene), pentoxifylline (Trental 400) and inositol nicotinate (Hexopal)

    Technology appraisal guidance
    Published
    View recommendations

  40. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)

    Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs

    Technology appraisal guidance
    Published
    View recommendations

  41. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)

    Evidence-based recommendations on rituximab (MabThera) for the maintenance treatment of follicular non-Hodgkin’s lymphoma in adults

    Technology appraisal guidance
    Published
    View recommendations

  42. Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

    Evidence-based recommendations on imatinib (Glivec) for treating unresectable (inoperable) and/or metastatic gastrointestinal stromal tumours (GISTs)

    Technology appraisal guidance
    Published
    View recommendations

  43. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

    Evidence-based recommendations on clopidogrel (Plavix) and modified-release dipyridamole (Persantin/Asasantin Retard) for preventing occlusive vascular events

    Technology appraisal guidance
    Published
    View recommendations

  45. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin) with oxaliplatin and fluorouracil plus folinic acid or capecitabine for metastatic colorectal cancer

    Technology appraisal guidance
    Published
    View recommendations

  46. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

    Evidence-based recommendations on aripiprazole (Abilify) for treating schizophrenia in people aged 15 to 17 years

    Technology appraisal guidance
    Published
    View recommendations

  48. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema secondary to retinal vein occlusion

    Technology appraisal guidance
    Published
    View recommendations

  49. Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

    Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

    Technology appraisal guidance
    Last updated
    View recommendations